Prior to joining the staff at the Sarah Cannon Research Institute and Tennessee Oncology in Nashville, Tennessee, Jesus G. Berdeja, MD, held appointments in the Stem Cell and Bone Marrow Transplant Program and the Division of Hematology and Oncology at Loma Linda University in Loma Linda, California.
Dr. Berdeja is a board-certified diplomate in internal medicine, medical oncology, and hematology by the American Board of Internal Medicine (ABIM). Additionally, he is an active member of several professional organizations, including the International Myeloma Society (IMS), the International Myeloma Working Group (IMWG), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the Clinical Trials Myeloma Intergroup Committee, and the Center for International Blood and Marrow Transplant Research (CIBMTR) Plasma Cell Working Group.
He is an active researcher and has been the principal investigator on several funded trials relating to the management of multiple myeloma, lymphoma, and other hematologic malignancies. He has authored articles in the peer-reviewed literature and is a frequent invited lecturer.
He received his undergraduate degree from Stanford University and medical degree from Harvard University. Dr. Berdeja completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore, Maryland.